Evidence map›Paper›PMID 39031289›Full record

ArticleMolecular diversity2025

Virtual screening and molecular dynamics simulation of natural compounds as potential inhibitors of serine/threonine kinase 16 for anticancer drug discovery.

Dhurgham Al-Fahad, G Ropón-Palacios, Damilola A Omoboyowa, Gagandeep Singh, Rajesh B Patil

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Identification of novel HIF2α inhibitors: a structure-based virtual screening approach.Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. AnBiochemistry and biophysics reports · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dhurgham Al-FahadDepartment of Pharmaceutical Science, College of Pharmacy, University of Thi-Qar, Nasiriyah, Iraq. dhurgham.alfahad@sci.utq.edu.iq.
G Ropón-PalaciosDepartment of Physics, IBILCE, São Paulo State University (UNESP), RuaCristóvão Colombo, 2265, São José Do Rio Preto, SP, CEP 15054-000, Brazil.
Damilola A OmoboyowaPhyto-Medicine and Computational Biology Laboratory, Department of Biochemistry, AdekunleAjasin University, Akungba-Akoko, Ondo, Nigeria.
Gagandeep SinghSection of Microbiology and Chemistry, Central Ayurveda Research Institute Jhansi, CCRAS, Ministry of Ayush, Jhansi, India.
Rajesh B PatilDepartment of Pharmaceutical Chemistry, Sinhgad Technical Education Society's, Sinhgad College of Pharmacy, Pune, India. rajshama1@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serine/threonine kinase 16 (STK 16) is involved in many facets of cellular regulation; activation of STK 16 plays a crucial role in the migration of cancer cells. Therefore, it is a novel target for the discovery of anticancer agents. Herein, virtual screening and dynamics simulation were used to screen a large library of natural compounds against STK 16 using Schrodinger suit 2021-2 and GROMACS 2021.6. The results predicted five molecules with high binding affinity against the target, with NPC132329 (Arcyriaflavin C) and NPC160898 having higher binding affinity and molecular mechanics generalized born surface area (MM/GBSA), suggesting that it is better than the standard inhibitor. The molecular dymanics (MD) simulation studies showed that the STK 16-NPC132329 complex has the lowest root mean square deviation, and STK 16-NPC160898 was the most stable compared with the standard drug and selective STK 16 inhibitor. The minimal fluctuation was observed in the STK 16-NPC132329 and STK 16-NPC160898 complexes based on the root mean square fluctuation trajectory with NPC132329 and NPC160898 forming 2 and 3 hydrogen bonds respectively with the amino acid residue of the target's binding site. Overall, NPC132329 and NPC160898 are better STK 16 inhibitors than the standard drug and selective inhibitor, which can be further studied to discover novel anticancer drugs.

Indexed as

Antineoplastic AgentsBiological ProductsDrug DiscoveryMolecular Dynamics SimulationProtein Kinase InhibitorsProtein Serine-Threonine KinasesDrug Evaluation, PreclinicalHumansMolecular Docking SimulationProtein BindingAntineoplastic AgentsBiological ProductsMARK4 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesGROMACSMD simulationMolecular dockingSchrodingerSTK 16

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.